Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

What have we learned from the current trials?

Kevin C Abbott1, George L Bakris

  • 1Nephrology Service, Walter Reed Army Medical Center, 6900 Georgia Avenue, Building 2, Ward 48, Washington, DC 20307-5001, USA.

The Medical Clinics of North America
|February 12, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Factitious acidosis and severe hypoalbuminemia caused by unsuspected assay interference.

Clinical kidney journal·2021
Same author

Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.

British journal of pharmacology·2021
Same author

Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.

Circulation·2021
Same author

Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial.

Journal of the American Society of Nephrology : JASN·2021
Same author

Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects.

Nature reviews. Nephrology·2021
Same author

Longitudinal Blood Pressure Patterns and Chronic Kidney Disease Progression: An Evolving Paradigm.

Hypertension (Dallas, Tex. : 1979)·2021
Same journal

Care Transitions Continue to Evolve.

The Medical clinics of North America·2026
Same journal

Navigating the Gaps: A Comprehensive Overview of Care Transitions Across the Continuum.

The Medical clinics of North America·2026
Same journal

Care Transitions and Value-Based Payment Models in the United States.

The Medical clinics of North America·2026
Same journal

Technology and Innovation in Care Transitions: Imagining the Future of Postdischarge Care.

The Medical clinics of North America·2026
Same journal

Primary Care, Specialists, and Hospitals: Bridging the Gaps in Communication and Coordination.

The Medical clinics of North America·2026
Same journal

Social Determinants of Health: Unique Considerations in Transitions of Care.

The Medical clinics of North America·2026
See all related articles

Diuretic therapy is as effective as ACE or CCB for high-risk hypertension patients. Angiotensin-converting enzyme inhibitors (ACE) are preferred for type I diabetes, while angiotensin II receptor blockers (ARBs) benefit type II diabetic nephropathy.

Area of Science:

  • Cardiology
  • Nephrology
  • Pharmacology

Background:

  • Randomized controlled trials (RCTs) for hypertension management have limitations, often raising more questions than answers.
  • Essential hypertension patients at high cardiovascular risk may achieve equivalent outcomes with diuretics compared to ACE inhibitors (ACE) or calcium channel blockers (CCB) alone.
  • Current treatment often combines diuretics with ACE or CCB, as seen in the RENAAL trial for type II diabetes with nephropathy.

Purpose of the Study:

  • To summarize current trial evidence on antihypertensive therapies for diverse patient populations.
  • To highlight the efficacy and appropriate use of diuretics, ACE, and ARBs in managing hypertension and related renal and cardiovascular complications.
  • To address the dilemma of prioritizing cardiovascular versus renal outcomes in patients with chronic kidney disease.

Related Experiment Videos

Main Methods:

  • Review and synthesis of findings from key randomized controlled trials including RENAAL, IDNT, HOPE, and AASK.
  • Analysis of treatment outcomes based on patient characteristics such as hypertension type, diabetes status, renal function, and ethnicity.
  • Examination of cardiovascular and renal disease progression data in relation to specific antihypertensive drug classes.

Main Results:

  • Diuretic monotherapy can be effective for essential hypertension, potentially offering cost benefits.
  • For African Americans with essential hypertension, ACE may offer advantages over CCBs or beta-blockers, with diuretics as a cornerstone.
  • Dihydropyridine CCBs (DHP CCB) are inappropriate as monotherapy for proteinuric renal disease; ACE inhibitors remain crucial for type I diabetes, while ARBs show greatest benefit for type II diabetic nephropathy.
  • ACE inhibitors, like ramipril, demonstrate significant cardiovascular event prevention in renal insufficiency, irrespective of diabetes status.
  • Patients with chronic kidney disease (serum creatinine ≥ 1.4 mg/dL) face significantly higher cardiovascular morbidity and mortality risks, underscoring the importance of ACE/ARB use.

Conclusions:

  • Treatment decisions for hypertension must be individualized, considering patient needs, medical factors, and economic implications.
  • ACE inhibitors and ARBs are crucial for patients with renal insufficiency and chronic kidney disease, with ARBs offering potential advantages in cough and hyperkalemia incidence.
  • Further large-scale RCTs are needed to definitively address the optimal management strategy balancing cardiovascular and renal outcomes in patients with compromised kidney function.